The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor

Mol Imaging Biol. 2004 May-Jun;6(3):126-30. doi: 10.1016/j.mibio.2004.03.003.

Abstract

Purpose: To compare the pre and post treatment 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging findings of an inflammatory myofibroblastic tumor (IMT) with its clinical response to immunosuppressive therapy.

Procedure: Forty-nine-year-old female presented with dyspnea, chest pain, and weight loss and underwent an FDG-PET/CT scan before and after mediastinal biopsy and treatment with dexamethasone and thalidomide.

Results: FDG-PET/CT scan demonstrated a hypermetabolic mediastinal mass. The biopsy of the lesion was consistent with IMT. Following immunosuppressive therapy, the patient's clinical findings resolved, and PET/CT showed a significant decrease in the FDG uptake and the size of the mass.

Conclusion: Pre-treatment imaging features and post-treatment imaging characteristics of IMT correlate with clinical findings and suggest that FDG-PET/CT may be useful as an adjunct to clinical evaluation in monitoring of immunosuppressive therapy of IMT.

MeSH terms

  • Female
  • Fluorodeoxyglucose F18*
  • Granuloma, Plasma Cell / diagnostic imaging*
  • Granuloma, Plasma Cell / drug therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Mediastinal Neoplasms / diagnostic imaging*
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinum / diagnostic imaging
  • Middle Aged
  • Positron-Emission Tomography*

Substances

  • Immunosuppressive Agents
  • Fluorodeoxyglucose F18